LytPhage, Inc is a start-up Biotech company developing novel antimicrobial products that harness genetically-modified bacterial viruses (bacteriophage/phage) for the treatment of antibiotic resistant bacterial infections. Phage infect and kill only specifically targeted bacteria as part of their natural life cycle. Phage can infect only the specific bacterial host cells (and not mammalian cells), so they are an attractive alternative therapy to current broad spectrum synthetic and natural product antimicrobials. The first product of LytPhage uses technology from the laboratory of Dr. Roy H. Stevens, Temple University, to target and treat resistant systemic and urinary tract infections caused by antibiotic resistant enterococci bacteria.
Stevens RH, Ektefaie MR, Fouts DE., 2011. "The annotated complete DNA sequence of Enterococcus faecalis bacteriophage phageEf11 and its comparison to all available phage and prophage genomes", FEMS Microbiol Lett, 317: 9-26, 2011.
Magil et al 2014, "Multistate Point-Prevalence Survey of Health Care-Associated Infections", NEJM
"Antibiotic Resistant Threats in the United States, 2013", US Dept. of Health & Human Services, Centers for Disease Control and Prevention.